glp 1 drug zepbound Eli Lilly's New $299 Month-Long GLP‑1 Injector Shows Why It's Winning the Weight‑Loss Race Dual GIP/GLP-1 Drug Linked to
Description
Most GLP-1 fatigue isnt a lack of willpower. Its your routine lagging behind your new appetite
Insulin resistance exacerbated pathological PD features which contributed to disease progression via increases in -synuclein accumulation in dopaminergic neurons, oxidative stress, and mitochondrial dysfunction
Animal studies serve an important role in identifying potential concerns that warrant human investigation
Based on Phase 2 trial data, Retatrutide achieved 24.2% weight loss versus tirzepatide's 20.9% (at a longer 72-week endpoint)
[PMID: 37940910]
